Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).

被引：105
|
作者：
Gao, Xin
Burris, Howard A., III
Vuky, Jacqueline
Dreicer, Robert
Sartor, A. Oliver
Sternberg, Cora N.
Percent, Ivor John
Hussain, Maha H. A.
Kalebasty, Arash Rezazadeh
Shen, John
Heath, Elisabeth I.
Abesada-Terk, Guillermo
Gandhi, Sunil G.
McKean, Meredith
Lu, Haolan
Berghorn, Elmer
Gedrich, Richard
Chirnomas, S. Debbie
Vogelzang, Nicholas J.
Petrylak, Daniel P.
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Sarah Cannon Res Inst & Tennessee Oncol, Nashville, TN USA
[3] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[4] Univ Virginia, Ctr Canc, Charlottesville, VA 22908 USA
[5] Tulane Canc Ctr, New Orleans, LA USA
[6] Weill Cornell Med, Englander Inst Precis Med, Hematol Oncol, New York, NY USA
[7] Florida Canc Specialists South, Port Charlotte, FL USA
[8] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA
[9] Univ Calif Irvine Med Ctr, Orange, CA USA
[10] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA
[11] Wayne State Univ, Karmanos Canc Inst, Sch Med, Detroit, MI USA
[12] Florida Canc Specialists East, W Palm Beach, FL USA
[13] Florida Canc Specialists North, St Petersburg, FL USA
[14] Arvinas Inc, New Haven, CT USA
[15] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[16] Yale Sch Med, Smilow Canc Ctr, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.017
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
17
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A phase 2 expansion study of ARV-766, a PROTAC androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC).
    Petrylak, Daniel P.
    Stewart, Tyler F.
    Gao, Xin
    Berghorn, Elmer
    Lu, Haolan
    Chan, Edward
    Gedrich, Richard
    Lang, Joshua Michael
    McKean, Meredith
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [2] ARV-110: An androgen receptor PROTAC degrader for prostate cancer
    Neklesa, Taavi
    Snyder, Lawrence B.
    Willard, Ryan R.
    Vitale, Nicholas
    Raina, Kanak
    Pizzano, Jennifer
    Gordon, Deborah
    Bookbinder, Mark
    Macaluso, Jennifer
    Dong, Hanqing
    Liu, Zheng
    Ferraro, Caterina
    Wang, Gan
    Wang, Jing
    Crews, Craig M.
    Houston, John
    Crew, Andrew P.
    Taylor, Ian
    CANCER RESEARCH, 2018, 78 (13)
  • [3] ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1/2 study
    Petrylak, Daniel P.
    McKean, Meredith
    Lang, Joshua Michael
    Gao, Xin
    Dreicer, Robert
    Geynisman, Daniel M.
    Stewart, Tyler F.
    Gandhi, Mitul
    Appleman, Leonard Joseph
    Dorff, Tanya B.
    Chatta, Gurkamal S.
    Tutrone, Ronald
    De la Cerda, Jose
    Berghorn, Elmer
    Gong, Jiachang
    Yu, Tinghui
    Dominy, Erin
    Chan, Edward
    Shore, Neal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer.
    Neklesa, Taavi
    Snyder, Lawrence B.
    Willard, Ryan R.
    Vitale, Nicholas
    Pizzano, Jennifer
    Gordon, Deborah A.
    Bookbinder, Mark
    Macaluso, Jennifer
    Dong, Hanqing
    Ferraro, Caterina
    Wang, Gan
    Wang, Jing
    Crews, Craig M.
    Houston, John
    Crew, Andrew P.
    Taylor, Ian
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [5] First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI).
    Petrylak, Daniel Peter
    Gao, Xin
    Vogelzang, Nicholas J.
    Garfield, Mary Harlow
    Taylor, Ian
    Moore, Marcia Dougan
    Peck, Ronald Alan
    Burris, Howard A., III
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] Discovery of ARV-110, a first in class androgen receptor degrading PROTAC for the treatment of men with metastatic castration resistant prostate cancer.
    Snyder, Lawrence B.
    Neklesa, Taavi K.
    Chen, Xin
    Dong, Hanqing
    Ferraro, Caterina
    Gordon, Deborah A.
    Macaluso, Jennifer
    Pizzano, Jennifer
    Wang, Jing
    Willard, Ryan R.
    Vitale, Nicholas
    Peck, Ron
    Moore, Marcia Dougan
    Crews, Craig M.
    Houston, John
    Crew, Andrew P.
    Taylor, Ian
    CANCER RESEARCH, 2021, 81 (13)
  • [7] Targeted androgen receptor (AR) protein degradation for the treatment of metastatic castration-resistant prostate cancer (mCRPC)
    Han, Xin
    Zhao, Lijie
    Xiang, Weiguo
    Qin, Chong
    Miao, Bukeyan
    Xu, Tianfeng
    Lu, Jianfeng
    Wang, Mi
    Wang, Shaomeng
    CANCER RESEARCH, 2020, 80 (16)
  • [8] Biomarker assessment and pharmacology of HP518, an AR PROTAC degrader from the phase 1 dose-escalation study in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Azad, Arun
    Underhill, Craig R.
    Gurney, Howard
    Horvath, Lisa
    Voskoboynik, Mark
    Ellerington, Scott
    Dai, Yiyun
    King, Ivan
    Perabo, Frank
    Guo, George
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Androgen receptor (AR) mutations in men with metastatic castration-resistant prostate cancer (mCRPC): Incidence and natural history.
    Bernard-Tessier, Alice
    Mulier, Guillaume
    Nay, Paula
    Baldini, Capucine
    Albiges, Laurence
    Colomba, Emeline
    Flippot, Ronan
    Lavaud, Pernelle
    Naoun, Natacha
    Patrikidou, Anna
    Loriot, Yohann
    Massard, Christophe
    Foulon, Stephanie
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [10] ARV-330: Androgen receptor PROTAC degrader for prostate cancer.
    Neklesa, Taavi K.
    Jin, Meizhong
    Crew, Andrew P.
    Rossi, AnnMarie K.
    Willard, Ryan R.
    Dong, Hanqing
    Siu, Kam
    Wang, Jing
    Gordon, Deborah A.
    Chen, Xin
    Ferraro, Caterina
    Crews, Craig M.
    Coleman, Kevin
    Winkler, James D.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
12345